|
US5614492A
(en)
*
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
|
US7138486B2
(en)
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
|
US6849708B1
(en)
|
1986-05-05 |
2005-02-01 |
The General Hospital Corporation |
Insulinotropic hormone and uses thereof
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
DK36392D0
(da)
*
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
|
USRE37302E1
(en)
*
|
1992-03-19 |
2001-07-31 |
Novo Nordisk A/S |
Peptide
|
|
DK36492D0
(da)
*
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Praeparat
|
|
EP0969016A2
(en)
*
|
1992-06-15 |
2000-01-05 |
Scios Inc. |
Glucagon-like peptide and insulinotropin derivates
|
|
NZ250844A
(en)
*
|
1993-04-07 |
1996-03-26 |
Pfizer |
Treatment of non-insulin dependant diabetes with peptides; composition
|
|
US6284727B1
(en)
*
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
US5705483A
(en)
*
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
|
EP0658568A1
(en)
*
|
1993-12-09 |
1995-06-21 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
|
DK144093D0
(enExample)
*
|
1993-12-23 |
1993-12-23 |
Novo Nordisk As |
|
|
GB9409496D0
(en)
*
|
1994-05-12 |
1994-06-29 |
London Health Ass |
Method for improving glycaemic control in diabetes
|
|
US5574008A
(en)
|
1994-08-30 |
1996-11-12 |
Eli Lilly And Company |
Biologically active fragments of glucagon-like insulinotropic peptide
|
|
US5512549A
(en)
*
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
|
US5990077A
(en)
*
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
|
WO1996036883A1
(en)
*
|
1995-05-17 |
1996-11-21 |
Novo Nordisk A/S |
Immunoassay for glucagon like protein 1 (glp-1) in plasma
|
|
US6852690B1
(en)
|
1995-08-22 |
2005-02-08 |
Amylin Pharmaceuticals, Inc. |
Method and composition for enhanced parenteral nutrition
|
|
DE19616486C5
(de)
*
|
1996-04-25 |
2016-06-30 |
Royalty Pharma Collection Trust |
Verfahren zur Senkung des Blutglukosespiegels in Säugern
|
|
DE122009000079I2
(de)
*
|
1996-08-30 |
2011-06-16 |
Novo Nordisk As Novo Alle |
Glp-1 derivate
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
EP1566180A3
(en)
*
|
1996-08-30 |
2007-08-08 |
Eli Lilly & Company |
Use of GLP-1 or Analogs in Treatment of Myocardial Infarction
|
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
US6277819B1
(en)
*
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
US6006753A
(en)
*
|
1996-08-30 |
1999-12-28 |
Eli Lilly And Company |
Use of GLP-1 or analogs to abolish catabolic changes after surgery
|
|
JP2000517308A
(ja)
*
|
1996-08-30 |
2000-12-26 |
ノボ ノルディスク アクティーゼルスカブ |
Ｇｌｐ―２誘導体
|
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
|
EP1629849B2
(en)
|
1997-01-07 |
2017-10-04 |
Amylin Pharmaceuticals, LLC |
Pharmaceutical compositions comprising exendins and agonists thereof
|
|
CA2283834A1
(en)
*
|
1997-03-31 |
1998-10-08 |
James Arthur Hoffmann |
Glucagon-like peptide-1 analogs
|
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
DE59811840D1
(de)
*
|
1997-09-12 |
2004-09-23 |
Pharis Biotec Gmbh |
Zusammensetzung zur therapie von diabetes mellitus und fettsucht
|
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
EP1066314B1
(en)
|
1997-11-14 |
2007-12-26 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
AU1617399A
(en)
*
|
1997-12-05 |
1999-06-28 |
Eli Lilly And Company |
Glp-1 formulations
|
|
EP2433623A1
(en)
|
1998-02-02 |
2012-03-28 |
Trustees Of Tufts College |
Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
|
|
AU2610899A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
AU2610799A
(en)
*
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
|
|
FR2777283B1
(fr)
*
|
1998-04-10 |
2000-11-24 |
Adir |
Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
JPH11328947A
(ja)
|
1998-05-18 |
1999-11-30 |
Nec Corp |
大規模ｆｉｆｏ回路
|
|
DE19823831A1
(de)
|
1998-05-28 |
1999-12-02 |
Probiodrug Ges Fuer Arzneim |
Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
|
|
DE19828114A1
(de)
|
1998-06-24 |
2000-01-27 |
Probiodrug Ges Fuer Arzneim |
Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
|
|
DE19828113A1
(de)
|
1998-06-24 |
2000-01-05 |
Probiodrug Ges Fuer Arzneim |
Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
|
|
EP1932535A3
(en)
|
1998-07-31 |
2008-10-29 |
Novo Nordisk A/S |
Stimulation of beta cell profileration
|
|
EP1666054A1
(en)
|
1998-08-28 |
2006-06-07 |
Eli Lilly & Company |
Method for administering insulinotropic peptides
|
|
CA2343268A1
(en)
|
1998-09-17 |
2000-03-23 |
Eli Lilly And Company |
Protein formulations
|
|
US6461834B1
(en)
|
1998-11-06 |
2002-10-08 |
Bionebraska, Inc. |
Clostripain catalyzed amidation of peptides
|
|
CN1495198A
(zh)
*
|
1998-12-07 |
2004-05-12 |
�о���Ӧ�ÿ�ѧЭ��ɷ�����˾ |
胰高血糖素样肽-1的类似物
|
|
ES2302390T3
(es)
*
|
1998-12-07 |
2008-07-01 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Analogos de glp-1.
|
|
CN1935839B
(zh)
*
|
1998-12-07 |
2012-06-06 |
益普生制药股份有限公司 |
胰高血糖素样肽-1的类似物
|
|
US7425541B2
(en)
|
1998-12-11 |
2008-09-16 |
Medarex, Inc. |
Enzyme-cleavable prodrug compounds
|
|
EP1600162A1
(en)
|
1998-12-22 |
2005-11-30 |
Eli Lilly & Company |
Shelf-stable formulation of glucagon-like peptide-1
|
|
US6927214B1
(en)
|
1999-01-15 |
2005-08-09 |
Novo Nordisk A/S |
Non-peptide GLP-1 agonists
|
|
US6444788B1
(en)
|
1999-03-15 |
2002-09-03 |
Novo Nordisk A/S |
Ion exchange chromatography of GLP-1, analogs and derivatives thereof
|
|
US6451987B1
(en)
|
1999-03-15 |
2002-09-17 |
Novo Nordisk A/S |
Ion exchange chromatography of proteins and peptides
|
|
EP1163268B1
(en)
|
1999-03-15 |
2011-05-11 |
Novo Nordisk A/S |
Ion exchange chromatographic separation of glp-1 and related peptides
|
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
|
JP4115671B2
(ja)
|
1999-05-17 |
2008-07-09 |
コンジュケム バイオテクノロジーズ インコーポレイテッド |
長期間持続するインシュリン向性ペプチド
|
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US6309633B1
(en)
*
|
1999-06-19 |
2001-10-30 |
Nobex Corporation |
Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
|
|
DE19940130A1
(de)
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
|
|
HK1048828A1
(zh)
*
|
1999-11-19 |
2003-04-17 |
Transkaryotic Therapies, Inc. |
可令生产优化的核酸构造
|
|
EP1741445B1
(en)
|
2000-01-21 |
2013-08-14 |
Novartis AG |
Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
|
|
JP2003525908A
(ja)
|
2000-03-08 |
2003-09-02 |
ノボ ノルディスク アクティーゼルスカブ |
血清脂質の低下
|
|
WO2001079444A2
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc |
Albumin fusion proteins
|
|
EA008837B1
(ru)
*
|
2000-06-16 |
2007-08-31 |
Эли Лилли Энд Компани |
Аналоги глюкагоноподобного пептида и их применение
|
|
AR033390A1
(es)
|
2000-08-22 |
2003-12-17 |
Novartis Ag |
Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
|
|
US6770620B2
(en)
|
2000-09-18 |
2004-08-03 |
Sanos Bioscience A/S |
Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
|
|
US7132104B1
(en)
|
2000-10-27 |
2006-11-07 |
Probiodrug Ag |
Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
|
|
DE60136958D1
(de)
|
2000-12-01 |
2009-01-22 |
Takeda Pharmaceutical |
Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
|
|
WO2002048192A2
(en)
|
2000-12-13 |
2002-06-20 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
|
US6890905B2
(en)
|
2001-04-02 |
2005-05-10 |
Prosidion Limited |
Methods for improving islet signaling in diabetes mellitus and for its prevention
|
|
CN1162446C
(zh)
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
|
US20030130199A1
(en)
|
2001-06-27 |
2003-07-10 |
Von Hoersten Stephan |
Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
|
|
US7368421B2
(en)
|
2001-06-27 |
2008-05-06 |
Probiodrug Ag |
Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
|
|
DE10150203A1
(de)
|
2001-10-12 |
2003-04-17 |
Probiodrug Ag |
Peptidylketone als Inhibitoren der DPIV
|
|
MXPA04001525A
(es)
|
2001-08-23 |
2004-05-31 |
Lilly Co Eli |
Analogos de peptido -1 similar al glucagon.
|
|
US6844316B2
(en)
|
2001-09-06 |
2005-01-18 |
Probiodrug Ag |
Inhibitors of dipeptidyl peptidase I
|
|
AR036711A1
(es)
|
2001-10-05 |
2004-09-29 |
Bayer Corp |
Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
|
|
US7041646B2
(en)
|
2001-10-05 |
2006-05-09 |
Bayer Pharmaceuticals Corporation |
Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
|
|
US6864069B2
(en)
|
2001-10-05 |
2005-03-08 |
Bayer Pharmaceuticals Corporation |
Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
|
|
EP2277888A3
(en)
|
2001-12-21 |
2011-04-27 |
Human Genome Sciences, Inc. |
Fusion proteins of albumin and erythropoietin
|
|
EP2409569B1
(en)
|
2002-02-20 |
2017-08-16 |
Emisphere Technologies, Inc. |
Method for administering GLP-1 molecules
|
|
EA007434B1
(ru)
|
2002-02-28 |
2006-10-27 |
Прозидион Лимитед |
Ингибиторы dpiv на основе глутаминила
|
|
EP2028192A1
(en)
|
2002-07-04 |
2009-02-25 |
Zealand Pharma A/S |
GLP-1 and methods for treating diabetes
|
|
EP1539210A4
(en)
*
|
2002-09-06 |
2006-06-07 |
Bayer Pharmaceuticals Corp |
GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE
|
|
US7273921B2
(en)
|
2002-09-25 |
2007-09-25 |
Novo Nordisk A/S |
Method for producing acylated peptides
|
|
WO2004029081A2
(en)
|
2002-09-25 |
2004-04-08 |
Theratechnologies Inc. |
Modified glp-1 peptides with increased biological potency
|
|
WO2004035624A2
(en)
|
2002-10-14 |
2004-04-29 |
Novo Nordisk A/S |
Glucagon - like peptide - 2 variants
|
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
|
EP1594530A4
(en)
|
2003-01-22 |
2006-10-11 |
Human Genome Sciences Inc |
HYBRID PROTEINS OF ALBUMIN
|
|
WO2004087053A2
(en)
|
2003-03-25 |
2004-10-14 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
|
EP2256189A1
(en)
|
2003-03-28 |
2010-12-01 |
National Institute Of Agrobiological Sciences |
Process for producing a plant storage organ in which a GLP-1 derivative recombinant protein is highly produced.
|
|
DK2206496T3
(da)
|
2003-05-05 |
2014-12-15 |
Probiodrug Ag |
Screening af inhibitorer af pyroglutaminsyredannelse i amyloid beta-peptid
|
|
DE602004026289D1
(de)
|
2003-05-05 |
2010-05-12 |
Probiodrug Ag |
Glutaminylcyclase-hemmer
|
|
JP2007511467A
(ja)
|
2003-05-14 |
2007-05-10 |
タケダ サン ディエゴ インコーポレイテッド |
ジペプチジルペプチダーゼインヒビター
|
|
US7008957B2
(en)
|
2003-07-25 |
2006-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
|
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
|
US7790736B2
(en)
|
2003-08-13 |
2010-09-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
RU2006103860A
(ru)
|
2003-08-21 |
2006-07-27 |
Ново Нордиск А/С (DK) |
Способ разделения полипептидов, содержащих рацемическую аминокислоту
|
|
EP2932981B1
(en)
|
2003-09-19 |
2021-06-16 |
Novo Nordisk A/S |
Albumin-binding derivatives of GLP-1
|
|
EP2289498A1
(en)
|
2003-10-15 |
2011-03-02 |
Probiodrug AG |
Use of inhibitors of glutaminyl clyclase
|
|
CA2545034C
(en)
|
2003-11-20 |
2013-03-05 |
Novo Nordisk A/S |
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
|
|
WO2005056036A2
(en)
|
2003-12-09 |
2005-06-23 |
Novo Nordisk A/S |
Regulation of food preference using glp-1 agonists
|
|
AR047776A1
(es)
*
|
2003-12-16 |
2006-02-22 |
Sod Conseils Rech Applic |
Composiciones farmaceuticas glp - 1
|
|
JP2007536214A
(ja)
|
2003-12-16 |
2007-12-13 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Ｇｌｐ−１類似体
|
|
CA2549582A1
(en)
|
2003-12-18 |
2005-06-30 |
Novo Nordisk A/S |
Novel glp-1 compounds
|
|
EP1709071A4
(en)
*
|
2004-01-08 |
2007-05-30 |
Theratechnologies Inc |
GLUCAGON LIKE PEPTIDE-1 ANALOGS WITH LONG PERFORMANCE
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
IN2012DN03921A
(enExample)
|
2004-02-11 |
2015-09-04 |
Amylin Pharmaceuticals Inc |
|
|
US8410047B2
(en)
|
2004-06-11 |
2013-04-02 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using GLP-1 agonists
|
|
WO2006091231A2
(en)
*
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
|
WO2006059106A2
(en)
|
2004-12-02 |
2006-06-08 |
Domantis Limited |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
|
EA011653B1
(ru)
|
2005-02-11 |
2009-04-28 |
Амилин Фармасьютикалз, Инк. |
Аналоги и гибридные полипептиды gip с избираемыми свойствами
|
|
WO2007022123A2
(en)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
MX2007011307A
(es)
|
2005-03-18 |
2007-10-08 |
Novo Nordisk As |
Compuestos de glp-1 extendidos.
|
|
EP1888103B1
(en)
|
2005-04-11 |
2012-03-21 |
Amylin Pharmaceuticals, Inc. |
Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
|
|
TW200722088A
(en)
*
|
2005-05-27 |
2007-06-16 |
Sankyo Co |
Diabetes remedy
|
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
|
PE20070522A1
(es)
|
2005-09-14 |
2007-07-11 |
Takeda Pharmaceutical |
2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo como inhibidor de dipeptidil peptidasa y composiciones farmaceuticas que lo contienen
|
|
GEP20135791B
(en)
|
2005-09-14 |
2013-03-25 |
Takeda Pharmaceutical |
Use of dipeptidyl peptidase inhibitors
|
|
US8222411B2
(en)
|
2005-09-16 |
2012-07-17 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
ES2397289T3
(es)
|
2005-09-22 |
2013-03-06 |
Biocompatibles Uk Ltd. |
Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
|
|
EP1943275B1
(en)
*
|
2005-11-01 |
2010-06-16 |
Activotec SPP Limited |
Insulinotropic compounds and uses thereof
|
|
CN101534846B
(zh)
|
2005-11-07 |
2014-11-05 |
印第安纳大学研究及科技有限公司 |
显示生理学溶解性和稳定性的胰高血糖素类似物
|
|
CN100374462C
(zh)
*
|
2005-11-21 |
2008-03-12 |
大连帝恩生物工程有限公司 |
截短胰高血糖素样肽1(sGLP-1)、制法及其应用
|
|
EP1961764B1
(en)
*
|
2005-11-30 |
2011-05-11 |
Shionogi Co., Ltd. |
Sugar chain adduct of peptide and pharmaceutical comprising the same as active ingredient
|
|
US8293869B2
(en)
|
2005-12-16 |
2012-10-23 |
Nektar Therapeutics |
Polymer conjugates of GLP-1
|
|
WO2007124461A2
(en)
|
2006-04-20 |
2007-11-01 |
Amgen Inc. |
Glp-1 compounds
|
|
EP3255149A3
(en)
*
|
2006-05-02 |
2018-04-18 |
Intrexon Actobiotics NV |
Microbial intestinal delivery of obesity related peptides
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
|
KR20090119876A
(ko)
|
2007-02-15 |
2009-11-20 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/ｇｌｐ-1 수용체 공동-항진물질
|
|
RU2350324C1
(ru)
*
|
2007-08-02 |
2009-03-27 |
Закрытое акционерное общество "Биологические исследования и системы" |
Способ лечения сахарного диабета 2 типа, осложненного полиневропатией
|
|
EP2190873B1
(en)
*
|
2007-09-05 |
2015-07-22 |
Novo Nordisk A/S |
Truncated glp-1 derivatives and their therapeutical use
|
|
ES2672770T3
(es)
|
2007-09-05 |
2018-06-18 |
Novo Nordisk A/S |
Derivados del péptido-1 similar al glucagón y su uso farmacéutico
|
|
AU2008318876B2
(en)
|
2007-10-30 |
2014-05-15 |
Indiana University Research And Technology Corporation |
Compounds exhibiting glucagon antagonist and GLP-1 agonist activity
|
|
AU2009210570B2
(en)
|
2008-01-30 |
2014-11-20 |
Indiana University Research And Technology Corporation |
Ester-based insulin prodrugs
|
|
JP2011517561A
(ja)
|
2008-03-31 |
2011-06-16 |
グラクソ グループ リミテッド |
薬物融合体および複合体
|
|
NZ589847A
(en)
|
2008-06-17 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Glucagon/glp-1 receptor co-agonists
|
|
CL2009001425A1
(es)
|
2008-06-17 |
2010-04-30 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal.
|
|
CN102112157B
(zh)
|
2008-08-06 |
2013-05-29 |
诺沃-诺迪斯克保健股份有限公司 |
具有延长的体内效能的缀合蛋白
|
|
WO2010054326A2
(en)
|
2008-11-07 |
2010-05-14 |
The General Hospital Corporation |
C-terminal fragments of glucagon-like peptide-1 (glp-1)
|
|
JP5756407B2
(ja)
|
2008-12-08 |
2015-07-29 |
ノヴォ ノルディスク アー／エス |
ポリペプチドの向流精製
|
|
PL2373681T3
(pl)
*
|
2008-12-10 |
2017-07-31 |
Glaxosmithkline Llc |
Kompozycje farmaceutyczne albiglutydu
|
|
CA2747499A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
|
CA2747825A1
(en)
|
2009-01-22 |
2010-07-29 |
Novo Nordisk Health Care Ag |
Stable growth hormone compounds
|
|
CN104127880A
(zh)
|
2009-03-27 |
2014-11-05 |
葛兰素集团有限公司 |
药用融合体和缀合物
|
|
EA201101621A1
(ru)
|
2009-05-15 |
2012-05-30 |
Новартис Аг |
Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
|
|
PE20120403A1
(es)
|
2009-05-15 |
2012-05-03 |
Novartis Ag |
Aril-piridinas como inhibidoras de sintasa de aldosterona
|
|
EP2594557B1
(en)
|
2009-05-28 |
2016-08-10 |
Novartis AG |
Substituted aminopropionic derivatives as neprilysin inhibitors
|
|
CN102448928B
(zh)
|
2009-05-28 |
2014-10-01 |
诺华股份有限公司 |
作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物
|
|
US9150632B2
(en)
|
2009-06-16 |
2015-10-06 |
Indiana University Research And Technology Corporation |
GIP receptor-active glucagon compounds
|
|
JP6086528B2
(ja)
|
2009-08-06 |
2017-03-01 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
長期のインビボ有効性を有する成長ホルモン
|
|
CA2774552A1
(en)
|
2009-09-30 |
2011-04-07 |
Glaxo Group Limited |
Drug fusions and conjugates with extended half life
|
|
WO2011041293A1
(en)
|
2009-09-30 |
2011-04-07 |
Takeda Pharmaceutical Company Limited |
Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
|
|
CN102712589B
(zh)
|
2009-11-17 |
2015-05-13 |
诺华股份有限公司 |
作为醛固酮合酶抑制剂的芳基-吡啶衍生物
|
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
|
EP2507234B1
(en)
|
2009-11-30 |
2014-03-12 |
Novartis AG |
Imidazole derivatives as aldosterone synthase inhibitors
|
|
JP5411366B2
(ja)
*
|
2009-12-16 |
2014-02-12 |
ノヴォ ノルディスク アー／エス |
二重アシル化ｇｌｐ−１誘導体
|
|
JP5980689B2
(ja)
|
2010-01-22 |
2016-08-31 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
安定な成長ホルモン化合物
|
|
AU2011208625C1
(en)
|
2010-01-22 |
2022-08-18 |
Novo Nordisk Health Care Ag |
Growth hormones with prolonged in-vivo efficacy
|
|
EP2528618A4
(en)
|
2010-01-27 |
2015-05-27 |
Univ Indiana Res & Tech Corp |
GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
|
|
HRP20140114T1
(hr)
|
2010-02-03 |
2014-03-14 |
Takeda Pharmaceutical Company Limited |
Inhibitori kinaze 1 koji reguliraju signal apoptoze
|
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
|
WO2011133948A2
(en)
|
2010-04-22 |
2011-10-27 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
|
KR20130098873A
(ko)
|
2010-04-27 |
2013-09-05 |
질랜드 파마 에이/에스 |
Glp-1 수용체 작용제 및 가스트린의 펩타이드 접합체 및 그의 용도
|
|
KR20130093470A
(ko)
|
2010-04-30 |
2013-08-22 |
가부시키가이샤산와카가쿠켄큐쇼 |
생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
|
|
CN103124739B
(zh)
|
2010-05-17 |
2015-11-25 |
贝达药业股份有限公司 |
一种新胰高血糖素样肽类似物、组合物及其用途
|
|
WO2011163012A2
(en)
|
2010-06-24 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
|
JP5912112B2
(ja)
|
2010-06-24 |
2016-04-27 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ |
アミド系インスリンプロドラッグ
|
|
WO2012054822A1
(en)
|
2010-10-22 |
2012-04-26 |
Nektar Therapeutics |
Pharmacologically active polymer-glp-1 conjugates
|
|
WO2012054861A1
(en)
|
2010-10-22 |
2012-04-26 |
Nektar Therapeutics |
Glp-1 polymer conjugates having a releasable linkage
|
|
WO2012061466A2
(en)
|
2010-11-02 |
2012-05-10 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
|
WO2012080471A1
(en)
|
2010-12-16 |
2012-06-21 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
|
BR112013015389A2
(pt)
|
2010-12-22 |
2016-11-22 |
Univ Indiana Res & Tech Corp |
análogo de glucagon exibindo atividade de receptor gip
|
|
US20130344524A1
(en)
|
2011-03-08 |
2013-12-26 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Analysis method
|
|
WO2012136790A1
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Compositions comprising fusion proteins or conjugates with an improved half -life
|
|
WO2012136792A2
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Cck compositions
|
|
HUE031405T2
(en)
|
2011-04-12 |
2017-07-28 |
Novo Nordisk As |
Double-acylated GLP-1 derivatives
|
|
PE20140724A1
(es)
|
2011-06-22 |
2014-07-10 |
Univ Indiana Res & Tech Corp |
Coagonistas del receptor de glucagon/glp-1
|
|
KR20140043793A
(ko)
|
2011-06-22 |
2014-04-10 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/glp-1 수용체 공동-작용물질
|
|
US9944687B2
(en)
|
2011-07-04 |
2018-04-17 |
Imperial Innovations Limited |
Compounds and their effects on feeding behaviour
|
|
EP2729157B1
(en)
|
2011-07-06 |
2019-01-16 |
The General Hospital Corporation |
A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
|
|
CN104039344A
(zh)
*
|
2011-10-28 |
2014-09-10 |
法瑞斯生物技术有限公司 |
用于防止心脏缺血-再灌注损伤的多肽
|
|
MX2014005351A
(es)
|
2011-11-03 |
2014-05-28 |
Zealand Pharma As |
Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
|
|
JP2015500823A
(ja)
*
|
2011-12-09 |
2015-01-08 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１アゴニスト
|
|
MY171146A
(en)
|
2012-03-22 |
2019-09-27 |
Novo Nordisk As |
Compositions of glp-1 peptides and preparation thereof
|
|
DK2827845T3
(en)
|
2012-03-22 |
2019-04-01 |
Novo Nordisk As |
COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
|
|
WO2013171570A1
(en)
|
2012-05-16 |
2013-11-21 |
Glaxo Group Limited |
Polypeptide loaded poca nanoparticles for oral administration
|
|
US9993430B2
(en)
|
2012-06-20 |
2018-06-12 |
Novo Nordisk A/S |
Tablet formulation comprising semaglutide and a delivery agent
|
|
RU2015101697A
(ru)
|
2012-06-21 |
2016-08-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Аналоги глюкагона, обладающие активностью рецептора gip
|
|
JP6224586B2
(ja)
|
2012-07-10 |
2017-11-01 |
武田薬品工業株式会社 |
注射用製剤
|
|
DK2875043T3
(en)
|
2012-07-23 |
2017-03-27 |
Zealand Pharma As |
glucagon
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
|
EP2956464B1
(en)
|
2013-02-14 |
2018-03-28 |
Novartis AG |
Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
|
|
EP2968469A4
(en)
|
2013-03-15 |
2016-08-31 |
Longevity Biotech Inc |
PEPTIDES COMPRISING NON-ENDOGENIC AMINO ACIDS AND METHODS OF MAKING AND USING SAME
|
|
WO2014166836A1
(en)
|
2013-04-05 |
2014-10-16 |
Novo Nordisk A/S |
Growth hormone compound formulation
|
|
CN105263957A
(zh)
|
2013-05-02 |
2016-01-20 |
葛兰素史克知识产权开发有限公司 |
治疗肽
|
|
PT2991671T
(pt)
|
2013-05-02 |
2018-11-05 |
Novo Nordisk As |
Dosagem oral de compostos de glp-1
|
|
HK1218298A1
(zh)
|
2013-07-25 |
2017-02-10 |
Novartis Ag |
用於治疗心力衰竭的环状多肽
|
|
UY35671A
(es)
|
2013-07-25 |
2015-02-27 |
Novartis Ag |
Bioconjugados de polipéptidos de apelina sintética
|
|
HRP20181505T1
(hr)
|
2013-10-17 |
2018-11-02 |
Zealand Pharma A/S |
Acilirani analozi glukagona
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
EP3066117B1
(en)
|
2013-11-06 |
2019-01-02 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
|
EA035466B9
(ru)
|
2013-11-06 |
2020-08-17 |
Зилэнд Фарма А/С |
Соединения и способы на основе двойного агониста гип и гпп-1
|
|
CA2965732A1
(en)
|
2014-10-29 |
2016-05-06 |
Zealand Pharma A/S |
Gip agonist compounds and methods
|
|
CN107406490A
(zh)
|
2015-01-23 |
2017-11-28 |
诺华股份有限公司 |
具有改善的半衰期的合成apelin脂肪酸缀合物
|
|
RU2735762C2
(ru)
|
2015-04-16 |
2020-11-06 |
Зилэнд Фарма А/С |
Ацилированный аналог глюкагона, его применение и способы получения
|
|
WO2017210100A1
(en)
*
|
2016-06-02 |
2017-12-07 |
Indiana University Research And Technology Corporation |
Glucagon-like peptide-1-t3 conjugates
|
|
JOP20190086A1
(ar)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
|
|
SG10201911851VA
(en)
|
2016-12-09 |
2020-02-27 |
Zealand Pharma As |
Acylated glp-1/glp-2 dual agonists
|
|
HRP20240485T1
(hr)
|
2017-08-24 |
2024-07-05 |
Novo Nordisk A/S |
Pripravci glp-1 i njihova upotreba
|
|
CN115109166B
(zh)
*
|
2017-11-24 |
2025-07-18 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的多结构域活性蛋白
|
|
MA53076B1
(fr)
|
2018-02-02 |
2023-11-30 |
Novo Nordisk As |
Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
|
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
|
CN113166101A
(zh)
|
2018-11-27 |
2021-07-23 |
诺华股份有限公司 |
作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物
|
|
EP3887388A1
(en)
|
2018-11-27 |
2021-10-06 |
Novartis AG |
Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
|
|
UY38485A
(es)
|
2018-11-27 |
2020-06-30 |
Novartis Ag |
Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
|
|
GB201917723D0
(en)
|
2019-12-04 |
2020-01-15 |
Nv Rose Llc |
Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
|
|
US20230093542A1
(en)
|
2020-02-18 |
2023-03-23 |
Novo Nordisk A/S |
Glp-1 compositions and uses thereof
|
|
CN114729060B
(zh)
|
2020-09-30 |
2022-11-25 |
北京质肽生物医药科技有限公司 |
多肽缀合物和使用方法
|
|
WO2023084449A1
(en)
|
2021-11-12 |
2023-05-19 |
Novartis Ag |
Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
|
|
AR127698A1
(es)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
|
|
CN116848243B
(zh)
|
2022-03-30 |
2024-03-19 |
北京质肽生物医药科技有限公司 |
多肽缀合物的液体药物组合物和其使用方法
|
|
CN114958883B
(zh)
*
|
2022-04-12 |
2023-01-31 |
北京惠之衡生物科技有限公司 |
一种表达glp-1类似物的重组工程菌及其构建方法
|
|
WO2024106505A1
(ja)
*
|
2022-11-16 |
2024-05-23 |
株式会社ポル・メド・テック |
豚臓器又はその由来物を含む移植材の製造方法
|
|
WO2024241229A1
(en)
|
2023-05-24 |
2024-11-28 |
Novartis Ag |
Naphthyridinone derivatives for the treatment of a disease or disorder
|